Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development

详细信息    查看全文

• 作者：Ricardo Costa^a ; ^{ricardo.costa@northwestern.edu} ; Ami N. Shah^c ; Cesar A. Santa-Maria^a ; ^b ; Marcelo R. Cruz^a ; Devalingam Mahalingam^d ; Benedito A. Carneiro^a ; ^b ; Young Kwang Chae^a ; ^b ; Massimo Cristofanilli^a ; ^b ; William J. Gradishar^a ; ^b ; Francis J. Giles^a ; ^b
• 关键词：Triple negative breast cancer ; Epidermal Growth Factor Receptor ; Targeted therapy ; mTOR
• 刊名：Cancer Treatment Reviews
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：53
• 期：Complete
• 页码：111-119
• 全文大小：609 K
• 卷排序：53

文摘

EGFR is commonly expressed in triple negative breast cancer. Monoclonal antibodies targeting EGFR failed to show significant activity. Pre-clinical data support interaction between EGFR and MET receptor. Data on EGFR signaling pathway and immune checkpoints is scarce.